Previous 10 | Next 10 |
Nabriva Therapeutics ( NBRV +6.7% ) announces that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for Xenleta (lefamulin) for injection when administered in the hospital inpatient setting. More news on: Nabriva Therapeut...
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland, Sept. 10, 2020 (GLOBE NE...
DUBLIN, Ireland, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two u...
Nabriva Therapeutics Plc (NBRV) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Gary Sender - Chief Financial Officer Ted Schroeder - Chief Executive Officer Francesco Maria Lavino - Chief Commercial Officer Jennifer Schranz - Chief Medical Officer...
The following slide deck was published by Nabriva Therapeutics plc in conjunction with their 2020 Q2 earnings Read more ...
Nabriva Therapeutics (NASDAQ: NBRV ) : Q2 GAAP EPS of -$0.30 misses by $0.15 . More news on: Nabriva Therapeutics plc, Earnings news and commentary, Healthcare stocks news, , Read more ...
-SIVEXTRO ® adds revenue generating product creating additional scale and synergies- -Relaunch of XENLETA ® and SIVEXTRO planned with targeted in-person promotion- -Conference call today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 06, 2020 (GLOBE NEWSWIRE) -- ...
DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter fi...
DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer...
- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of antimicrobial stewardship DUBLIN, J...
News, Short Squeeze, Breakout and More Instantly...
Nabriva Therapeutics plc Company Name:
NBRV Stock Symbol:
NASDAQ Market:
-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV) today announced that, after an assessment ...
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Na...
- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30 p.m. Eastern Time - DUBLIN, Ireland, ...